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ABSTRACT
Objective: To examine the association between
classes of antidepressants and hyponatremia, and
between specific antidepressants and hyponatremia.
Design: Retrospective register-based cohort study
using nationwide registers from 1998 to 2012.
Setting: The North Denmark Region.
Participants: In total, 638 352 individuals were
included.
Primary and secondary outcome measures:
Plasma sodium was obtained from the LABKA database.
The primary outcome was hyponatremia defined as
plasma sodium (p-sodium) below 135 mmol/L and
secondary outcome was severe hyponatremia defined as
p-sodium below 130 mmol/L. The association between
use of specific antidepressants and hyponatremia was
analysed using multivariable Poisson regression models.
Results: An event of hyponatremia occurred in 72 509
individuals and 11.36% (n=6476) of these events
happened during treatment with antidepressants.
Incidence rate ratios and CIs for the association with
hyponatremia in the first p-sodium measured after
initiation of treatment were for citalopram 7.8 (CI 7.42 to
8.20); clomipramine 4.93 (CI 2.72 to 8.94); duloxetine
2.05 (CI 1.44 to 292); venlafaxine 2.90 (CI 2.43 to 3.46);
mirtazapine 2.95 (CI 2.71 to 3.21); and mianserin 0.90
(CI 0.71 to 1.14).
Conclusions: All antidepressants except mianserin are
associated with hyponatremia. The association is
strongest with citalopram and lowest with duloxetine,
venlafaxine and mirtazapine.
BACKGROUND
The consumption of antidepressants has
increased signiﬁcantly in most Organisation
for Economic Co-operation and Development
(OECD) countries since 2000. Denmark is
among the OECD countries with the highest
consumption.1
Hyponatremia is one of the many well-
known side effects of antidepressants.2 3 Even
mild hyponatremia is associated with instability
and falls, reduced cognitive function, osteopor-
osis and increased morbidity and mortality.4–13
The kidneys control the renal excretion of
water and electrolytes and keep serum osmo-
lality and sodium within a narrow range.
Several hormones inﬂuence the renal hand-
ling of water and electrolytes, the most
important being arginine vasopressin, also
known as antidiuretic hormone (ADH).
ADH binds to V2 receptors in the kidney,
and thereby leads to an increase in reabsorp-
tion of water in the collecting ducts. The
main stimuli for ADH is plasma osmolality
and low plasma volume, but a number of non-
speciﬁc stimuli like stress and nausea can also
result in elevated ADH concentrations.14 15
The presence of hypotonic hyponatremia
always implies excess of water, and hyponatre-
mia essentially is a water balance disorder.16 In
most cases of hypotonic hyponatremia, ADH
secretion is increased due to one of the follow-
ing reasons: (1) appropriate response to
decreased effective plasma volume as in hypo-
volaemia, cirrhosis and heart failure; (2)
ectopic production as seen in neoplastic dis-
eases resulting in syndrome of inappropriate
ADH (SIADH); or (3) syndrome of inappropri-
ate antidiuresis (SIAD) either due to a drug
induced increase in ADH production (SIADH)
or an enhanced renal response to ADH, the
nephrogenic syndrome of antidiuresis.16
Strengths and limitations of this study
▪ Large population study including all individuals
living in The North Denmark Region.
▪ Owing to the large number of individuals
included, it was possible to compare strengths
of associations between specific antidepressants
and occurrence of hyponatremia.
▪ Linking between several national registers of
high quality made it possible to adjust for
comorbidity and limited missing data.
▪ Observational design.
▪ Confounding by indication cannot be fully
excluded.
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In a cross-sectional study of elderly users of antidepres-
sants, Mannesse et al studied the mechanisms of hyponatre-
mia in 34 patients with hyponatremia. Data on serum and
urinary sodium were available in 30 patients, and of these
23 were classiﬁed as having either SIADH or probable
SIADH. However, only in a minority of these patients was
ADH not suppressed, and the authors concluded that the
mechanism of hyponatremia produced by antidepressants
might be either an elevated ADH or an increased renal
response to ADH.17 Some previous studies have examined
the relationship between hyponatremia and antidepres-
sants.18–23 However, most studies are small and observa-
tional and only few have had the power to examine whether
speciﬁc antidepressants carry a higher or lower risk of hypo-
natremia. The number of case reports and small observa-
tional studies with hyponatremia concerning selective
serotonin reuptake inhibitors (SSRI) is substantially higher
than the number of case reports and observational studies
with other antidepressants, but it is not clear whether this is
due to a true difference in incidence of hyponatremia.24
A recent review concluded that current evidence suggests a
relatively higher risk of hyponatremia with SSRIs and venla-
faxine compared to tricyclic antidepressants (TCA) and mir-
tazapine, but for several antidepressants, data were
insufﬁcient to determine the risk of hyponatremia.24
The aim of this study was to examine the association
between speciﬁc classes of antidepressant medication and
hyponatremia and between speciﬁc drugs within these
classes and hyponatremia. We examined the most com-
monly used drugs among TCA, SSRI, serotonin–norepin-
ephrine reuptake inhibitors (SNRIs) and noradrenergic
and speciﬁc serotonergic antidepressants (NaSSAs).
METHODS
By the time of birth or immigration, every Danish citizen
gets a permanent personal identiﬁcation number through
the Danish Civil Registration System. This makes it possible
to link information from multiple registers at the individ-
ual level. The current study is a register-based population
study where we linked exposure to antidepressant therapy
with occurrence of hyponatremia. We used information
from the Danish Civil Registration System, the Danish
National Patient Register, the Danish register of Medicinal
Products Statistics and laboratory data. Since 1968, the
Danish Civil Registration has been complete regarding
information about dates of birth and death for all Danish
citizens.25 The Danish National Patient Register contains
records of all hospitalisations since 1977.26 The Danish
Register of Medicinal Products Statistics consists of all pre-
scription claims from Danish pharmacies since 1995,
including medicine strength, quantity and date.27 The pre-
scriptions are classiﬁed according to the Anatomical
Therapeutic Chemical system (ATC).
Laboratory data
Information concerning p-sodium was obtained from the
LABKA database containing results of all blood samples
from hospitalised patients and outpatients submitted for
analyses to hospital laboratories in the Northern and
Central Denmark. From the database, information on
the date and result of the analysis was retrieved.
Population
All individuals born before 1998 and living in The
North Denmark Region in the period from 1 January
1998 to 31 December 2012 were included. Individuals
born after 1 January 1998 were excluded.
We continuously included individuals who immigrated
to The North Denmark Region in the study period.
Individuals were followed until end of study, emigration,
death or an event of hyponatremia, whichever occurred
ﬁrst.
Outcome assessment
Primary outcome was an event of hyponatremia deﬁned
as plasma sodium (p-sodium) below 135 mmol/L.
Secondary outcome was severe hyponatremia deﬁned as
p-sodium below 130 mmol/L. Since the prescription
register does not include medicine administered during
hospital stay, hyponatremia during hospitalisation was
excluded; however, the ﬁrst blood test after admission
was included if it was drawn on the day of admission.
Antidepressant therapy
We decided to include only the most commonly used anti-
depressants in Denmark. Information regarding anti-
depressant therapy was retrieved from the Danish National
Prescription Register and included the following
drugs (ATC codes in brackets): Amitriptyline (N06AA09),
Clomipramine (N06AA04) and Nortriptyline (N06AA10),
Citalopram (N06AB04), Escitalopram (N06AB10),
Fluoxetine (N06AB03), Paroxetine (N06AB05) and
Sertraline (N06AB06), Duloxetine (N06AX21),
Venlafaxine (N06AX16) and Mirtazapine (N06AX11),
Mianserin (N06AX03). Treatment was deﬁned in a time-
dependent manner; thus, we only considered individuals
as exposed if they were covered by a prescription claim.
Every prescription in the prescription register contains
data on tablet strength and number of tablets. To deter-
mine exposure status, we deﬁned minimum, maximum
and typical daily dosage for each drug and tablet strength.
On the basis of this information, we calculated length of
treatment by creating an algorithm that used up to ﬁve
consecutive prescriptions. These calculations were exclu-
sively based on previous prescription claims. When it was a
patient’s ﬁrst prescription claim, the typical daily dosage
was used and the amount of claimed medications was
divided by the daily dosage to determine length of treat-
ment. When a patient who was covered by a previous pre-
scription claimed a new one, we calculated a new daily
dosage by dividing the amount of claimed medications in
the previous period by the time between prescription
claims. If the calculated new daily dosage was higher than
the stated maximum dosage, this dosage was used instead.
It was presumed that the remaining tablets were kept and
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consumed immediately after the last prescription coverage
ended.
Comorbidities and concurrent pharmacotherapy
The following comorbidities were identiﬁed as possible
confounders of the association (The International
Statistical Classiﬁcation of Diseases and Related Health
Problems 10th Revision, (ICD10) codes in brackets):
chronic lung ( J40–47, J60–J70, J80, J82–J84, J95–J99),
liver (K70–K77), kidney (N18, N19), and intracranial
(I60–I69) diseases, heart failure (I50) and cancer (C).
These comorbidities were accessed from the Danish
National Patient Register. All comorbidities were identi-
ﬁed from 1993 and throughout the study period.
Furthermore, we identiﬁed treatment with antiepileptic
drugs or diuretics since these treatments could poten-
tially confound the association. As for the antidepressant
drugs, we deﬁned treatment in a time-dependent
manner, and treatment length was calculated in the
same way.
Statistics
The incidence rate ratio (IRR) of hyponatremia asso-
ciated with exposure to antidepressant therapy was
analysed in a time-dependent multivariable Poisson
regression model. Before the analyses, we divided observa-
tional time into 1 year timebands. Age was updated at the
beginning of each timeband and afterwards categorised
into 10-year intervals. At the time of a new diagnosis or
change in medication, the observational time was divided
into a ‘pre’ and a ‘post’ period, ensuring a timely correct
classiﬁcation of comorbidities and exposure to pharmaco-
therapy. Hereafter, binary variables (current use or no
use) were created for each antidepressant. Furthermore,
we divided time after ﬁrst prescription into ﬁve time-
bands: 0–14, 15–30, 31–90, 91–180 and >180 days.
We performed ﬁve different multivariable Poisson ana-
lyses: (1) estimating IRR for having p-sodium <135 with
current use of antidepressants; (2) estimating IRR for
having p-sodium <130; (3) estimating IRR for having
p-sodium measured after initiating treatment with the
different antidepressants; (4) estimating IRR for hypona-
tremia after initiating treatment (in each of the previ-
ously mentioned timebands) with one of the included
antidepressants. Owing to few events in some of the
strata in this analysis, we explored the association
between hyponatremia and four classes of antidepres-
sants (TCAs, SSRIs, SNRIs and NaSSAs); (5) estimating
IRR for hyponatremia in the ﬁrst p-sodium measure-
ment after initiating treatment. For the unexposed indi-
viduals we used their ﬁrst p-sodium measurement after
inclusion. Lastly, we made a subgroup analysis, only
including individuals who had p-sodium measured. To
avoid conditioning on the future, this was done in a
logistic regression analysis instead of a time-dependent
regression. In this analysis, we estimated the ORs for
hyponatremia with current use of antidepressants, as for
the Poisson regression analyses an individual was only
considered exposed if covered by a prescription claim.
All analyses were adjusted for age (in 10-year intervals),
sex, comorbidities and concurrent pharmacotherapy
with diuretics, antiepileptic drugs and other antidepres-
sants; furthermore, all Poisson regression analyses were
adjusted for time.
All analyses were performed using SAS V. 9.2 (SAS
Institute).
RESULTS
In total, 638 352 individuals were included in the study,
and they were on average followed for 10.98 years. Of
these, 15.50% (n=98 976) initiated treatment with an
antidepressant drug. An event of hyponatremia occurred
in 72 509 (11.36%) individuals, and 8.90% (n=6476) of
these events happened during treatment with antidepres-
sants. Population characteristics for individuals exposed
to the different antidepressants during follow-up and for
unexposed individuals are shown in table 1.
During follow-up, 60.28% (n=403.109) of the study
population had their p-sodium measured. 75% of indivi-
duals who started treatment with antidepressants had p-
sodium measured at some point during follow up, but
only 31% had p-sodium measured within the ﬁrst 6
months after initiation of treatment. The percentage of
individuals who had p-sodium measured within
6 months after initiating treatment varied between
drugs; the data are available in online supplementary
appendix A.
Figure 1 shows the association between use of speciﬁc
antidepressants and an event of hyponatremia and the
chance of having serum sodium measured while being in
treatment with an antidepressant. Drugs associated with a
high chance of having p-sodium measured were also
strongly associated with the ﬁnding of hyponatremia. We
therefore performed a logistic regression analysis in the
subpopulation of individuals who had p-sodium mea-
sured. This subpopulation included 403 109 individuals;
20.25% of these (n=81 618) were at some point in treat-
ment with an antidepressant. Figure 2 shows the associ-
ation between use of antidepressants and hyponatremia
in this subpopulation. The pattern of associations
between use of speciﬁc antidepressants and hyponatre-
mia in the subpopulation is very similar to the results in
the total population. Clomipramine (OR 4.15, CI 2.56 to
6.74) and nortriptyline (OR 2.44, CI 1.99 to 3.00) are
strongly associated with hyponatremia, but there are few
events leading to uncertainty in data and wide CIs.
Mianserin (OR 1.25, CI 0.96 to 1.62), mirtazapine (OR
1.53, CI 1.39 to 1.69) and escitalopram (OR 1.12, CI 0.98
to 1.29) have a weaker association with hyponatremia
than with citalopram (OR 2.34, CI 2.20 to 2.48). In order
to avoid possible bias due to some individuals having
p-sodium measured several times and thereby possibly
increasing the chance of catching an event of hyponatre-
mia, we performed a Poisson analysis to estimate IRR of
hyponatremia in the ﬁrst measurement of p-sodium after
having initiated treatment with an antidepressant. This
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analysis showed a slightly different pattern with highest
IRR for citalopram (7.80, CI 7.42 to 8.20); the results are
shown in ﬁgure 3. We also investigated the occurrence of
hyponatremia relative to the time of initiating treatment
with an antidepressant. For all antidepressants, the associ-
ation between treatment and occurrence of hyponatre-
mia was strongest in the ﬁrst 2 weeks after initiation and
thereafter gradually declined; the data are shown in
ﬁgure 4.
Finally, we looked at the occurrence of severe hypona-
tremia, deﬁned as p-sodium <130 mmol/L. The pattern
of association was not different from mild hyponatremia,
but due to fewer events the results are less clear with an
overlap of CIs for most drugs; the data are available in
online supplementary appendix B.
DISCUSSION
In this large register-based study including ∼10% of the
total Danish population living in a geographically well-
deﬁned area (The North Denmark Region), we investi-
gated the association between different antidepressants
and incidence of hyponatremia. We observed that all the
included antidepressants except mianserin were signiﬁ-
cantly associated with hyponatremia.
For all drugs, we found the highest IRR for hyponatre-
mia during the ﬁrst 14 days of treatment. This is consist-
ent with previous studies28 29 and, with the assumed
SIAD mechanism since the distribution and effect of
ADH, occurs within a few hours. This has been demon-
strated in studies concerning thiazide where changes in
plasma osmolality and p-sodium were observed within
6 h after a single dose of thiazide.30 31
Definition of hyponatremia
In this study, we deﬁned hyponatremia as p-sodium
<135. We have chosen this deﬁnition due to the fact that
even mild hyponatremia during recent years has been
shown to be of clinical importance.
Recently, an expert panel judged even mild hyponatre-
mia to be of clinical importance due to association with
adverse outcomes including mortality.32 A German study
found mean p-sodium 131 mmol/L in psychiatric inpati-
ents who were deemed to have symptomatic hyponatremia.
Symptoms were primarily neuropsychiatric such as confu-
sion, dizziness, gait impairments and falls.33Hyponatremia
due to any cause demonstrates an imbalance in the
homeostatic system that normally controls p-sodium, and
therefore even mild hyponatremia warrants cautiousness
when considering medical treatment and medical advice
concerning liquid and nutrition. One study even showed
the level of p-sodium when patients were admitted to hos-
pital to be associated with in-hospital mortality with a
cut-off at p-sodium of <138 mmol/L.34
Comparison of drug classes
We have performed several analyses in order to minim-
ise the bias that is inherent in an observational study.
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Most of the analyses presented show similar results, but
there are slight differences between the analyses pre-
sented. When comparing the speciﬁc drugs, we consider
the analysis of association between drug treatment and
hyponatremia in the ﬁrst p-sodium measured to give the
most valid and less biased results (ﬁgure 3). In this ana-
lysis, we have minimised the bias that may result from
some individuals having p-sodium measured many times
and some having p-sodium measured just once.
Furthermore, on the basis of knowledge concerning
pathophysiology of hyponatremia, we would expect
hyponatremia due to an antidepressant to be present in
the ﬁrst p-sodium measured. TCAs and SSRIs in this ana-
lysis show IRRs for hyponatremia at the same level.
The initial reports of antidepressants associated with
hyponatremia concerned TCA, but only a few later
studies have compared the incidence of hyponatremia
in TCAs with other antidepressants. In a large register-
based study, Coupland et al found a weaker association
between hyponatremia and TCAs compared to SSRIs.
However, Coupland’s study included only persons above
the age of 65. We cannot therefore directly compare the
results of Coupland’s study with those of our study.23
The SNRIs including duloxetine and venlafaxine have
lower IRRs. This is contradictory to another study that
examined venlafaxine.21 However, this study had a very
different population (patients in a psychiatric depart-
ment) and only a few venlafaxine cases. To the best of
Figure 1 Incidence rate ratios of having an episode of hyponatremia while being in treatment with an antidepressant and
incidence rate ratios of having p-sodium measured while being in treatment with an antidepressant.
Figure 2 ORs for hyponatremia for specific antidepressants in the subpopulation of individuals (n=403 109) who had p-sodium
measured.
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our knowledge, duloxetine has previously been studied
only in a case report including ﬁve cases.35
The NaSSAs include mianserin and mirtazapine. The
IRR for mirtazapine was similar to that for duloxetine
and venlafaxine. In contrast, mianserin was not asso-
ciated with hyponatremia. On the basis of case reports
and results from case series, it is generally assumed that
mirtazapine has a lower risk of hyponatremia than
SSRIs.20 24 Our results support this assumption since the
IRR for mirtazapine is signiﬁcantly lower compared to
SSRIs, but not compared to SNRIs. Mianserin and mirta-
zapine both block α2-adrenergic receptors, thereby
increasing the level of norepinephrine. Interestingly, the
α2-adrenergic system has been shown to be involved in
polydipsia in patients with schizophrenia in a small pilot
study where mianserin was used as treatment for
polydipsia.36 The fact that mirtazapine also blocks postsy-
naptic serotonergic receptors might explain the differ-
ence between mianserin and mirtazapine.
Mechanism of antidepressant-induced hyponatremia
It is assumed that the mechanism of antidepressant
hyponatremia is SIAD with or without elevated ADH.17
However, no studies have explored the inﬂuence of
antidepressant-induced hyponatremia on thirst. One
study has demonstrated that there is a downward setting
of the osmotic threshold for thirst in patients with
SIADH.37 Thiazide induced hyponatremia, which is also
believed to be induced by an SIADH mechanism, has
been associated with increased thirst.30 Combined with
the assumption that the α2-adrenergic system is involved
in polydipsia, this may explain why mianserin is not
Figure 3 Incidence rate ratios for hyponatremia in the first measurement of p-sodium level after initiating treatment with a
specific antidepressant.
Figure 4 Incidence rate ratios for hyponatremia in timebands after initiating antidepressant therapy with drugs belonging to
tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), serotonin–norepinephrine reuptake inhibitors
(SNRIs), and noradrenergic and specific serotonergic antidepressants (NaSSAs).
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associated with hyponatremia and mirtazapine to a
lesser degree than other antidepressants.
Clinical relevance and implications
Incidence of hyponatremia increases with age, which is
not surprising seen in the light of age-associated
changes in water homeostasis.38 39 Even mild hyponatre-
mia inﬂuences performance on cognitive as well as
balance and mobility testing in elderly individuals.4 5
Chronic hyponatremia is associated with osteoporosis
and high fracture risk.40 41 Furthermore, mild hypona-
tremia is an indicator of a water balance disorder, which
under different circumstances may develop into severe
and life-threatening hyponatremia. This is underlined by
the fact that patients, who for any reason have had hypo-
natremia once, are likely to have recurrent hyponatre-
mia as a response to different diseases and stimuli, and
lower baseline p-sodium is a risk factor for developing
hyponatremia.42 43 Even mild hyponatremia therefore
warrants cautious evaluation and, if possible, should be
abolished. The results from our study can inform the
choice of antidepressants, especially when treating
patients who are known to have a high risk of hyponatre-
mia like, for instance, elderly people and persons who
have previously had hyponatremia.
Strengths and limitations
The main strengths of this study are the large and well-
deﬁned population and high-quality registers, which
made it possible to examine speciﬁc antidepressants.
The limitations are mainly those that are inherent in an
observational study, that is, residual confounding due to
differences between patients and controls not accounted
for because of lack of information on other variables
that could possibly inﬂuence the risk of hyponatremia
like, for instance, eating and drinking habits. Although
we have adjusted for comorbidities and drugs known to
be able to induce hyponatremia, we cannot fully exclude
residual cofounding due to other reasons for hyponatre-
mia. Not all persons who were treated with antidepres-
sants had p-sodium measured and measurement may
have been performed due to symptoms of hyponatre-
mia. On the other hand, the symptoms of mild hypona-
tremia are often not recognised, and in elderly persons
they may even be mistaken for symptoms of normal
ageing (forgetfulness, dizziness, drowsiness). If the
patients who had p-sodium measured represent a selec-
tion of more symptomatic patients, we would overesti-
mate the rates of hyponatremia. However, an analysis
including only those individuals in the population who
had p-sodium measured showed similar results, which
means that comparison between drugs should be safe.
Thus, we consider the comparison of drugs valid, but we
cannot be certain about the absolute level of IRRs for
the speciﬁc drugs. The study population is Caucasian,
and therefore generalisation of the results to different
populations should be done with caution.
Comedication can increase or decrease the functional
activity of hepatic cytochrome enzymes (CYP) and, as such,
inhibit or induce the metabolic pathway of antidepres-
sants.44 45 Since the CYP activity determines the plasma
concentration of antidepressants and/or their metabolites
that will be achieved as a function of the dose adminis-
tered, drug–drug interactions may change the risk of dose-
dependent adverse drug events. In this study, potential
drug–drug interactions were not taken into account.
Conclusion
There is an increased risk of hyponatremia for all
included antidepressants, except for mianserin. The
strongest association between hyponatremia and antide-
pressants is found in SSRIs. The association with SNRIs
is slightly lower and the weakest association is with
NaSSAs. The risk of hyponatremia is highest within the
ﬁrst 2 weeks of treatment. Considering the possible
serious adverse effects of chronic hyponatremia, we rec-
ommend routine measurement of p-sodium shortly after
initiating treatment with any antidepressant.
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